MOLECULIN BIOTECH, INC. (NASDAQ:MBRX) Files An 8-K Other EventsItem 8.01 Other Events.
On November 29, 2017, Moleculin Biotech, Inc. (the “Company”) was informed that the physician-sponsored Investigational New Drug application made by MD Anderson Cancer Center for a Phase I trial of the Company's licensed drug compound WP1066 in patients with recurrent malignant glioma and brain metastasis from melanoma has been allowed by the U.S. Food and Drug Administration.
About MOLECULIN BIOTECH, INC. (NASDAQ:MBRX)
Moleculin Biotech, Inc. is a preclinical and clinical-stage pharmaceutical company. The Company is focused on the development of anti-cancer drug candidates. Its lead drug candidate is liposomal Annamycin, which it refers to as Annamycin, an anthracycline intended for the treatment of relapsed or refractory acute myeloid leukemia (AML). Annamycin is a Phase II clinical-stage anthracycline and liposome formulated anthracycline that has been designed to eliminate cardiotoxicity and avoid the multidrug resistance mechanisms. It has over two other drug development projects in progress, one involving a portfolio of small molecules, which it refers to as the WP1066 Portfolio, focused on the modulation of key oncogenic transcription factors involved in the progression of cancer, and the WP1122 Portfolio, a suite of molecules targeting the metabolic processes involved in cancer in general, and glioblastoma. As of September 30, 2016, it had not generated any revenue from its operations.
